Phase II Multicenter, Non Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 06 Jun 2017 Interim results (n = 19) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 03 May 2017 Status changed from recruiting to active, no longer recruiting.
- 06 May 2016 Status changed from not yet recruiting to recruiting.